Publikationen in Zusammenarbeit mit Forschern von King's College London (53)

2024

  1. Anticoagulant and non-anticoagulant therapy in thrombotic antiphospholipid syndrome: old drugs and new treatment targets

    Rheumatology (United Kingdom), Vol. 63, Núm. SI, pp. SI96-SI106

  2. Damage measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in antiphospholipid antibody-positive patients included in the APS ACTION registry

    Rheumatology (United Kingdom), Vol. 63, Núm. 3, pp. 772-779

  3. Thrombosis recurrence and major bleeding in non-anticoagulated thrombotic antiphospholipid syndrome patients: Prospective study from antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) clinical database and repository (“Registry”)

    Seminars in Arthritis and Rheumatism, Vol. 65

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Associations Among Antiphospholipid Antibody Types, Isotypes, and Titers: An AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Study

    Laboratory investigation; a journal of technical methods and pathology, Vol. 103, Núm. 6, pp. 100147

  3. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

  4. Fluctuation of Anti–Domain 1 and Anti–β2-Glycoprotein I Antibody Titers Over Time in Patients With Persistently Positive Antiphospholipid Antibodies

    Arthritis and Rheumatology, Vol. 75, Núm. 6, pp. 984-995

2022

  1. Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity

    Human Genetics, Vol. 141, Núm. 1, pp. 147-173

  2. Immunosuppression use in primary antiphospholipid antibody-positive patients: Descriptive analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

    Lupus, Vol. 31, Núm. 14, pp. 1770-1776

  3. Multicentre evaluation of two multiplex PCR platforms for the rapid microbiological investigation of nosocomial pneumonia in UK ICUs: the INHALE WP1 study

    Thorax, Vol. 77, Núm. 12, pp. 1220-1228

  4. What are the prospects for antiplatelet agents for thromboprophylaxis in antiphospholipid syndrome?

    Expert Review of Clinical Immunology

2021

  1. Antiphospholipid antibody profile stability over time: Prospective results from the APS ACTION clinical database and repository

    Journal of Rheumatology, Vol. 48, Núm. 4, pp. 541-547

  2. Clinical and laboratory characteristics of Brazilian versus non-Brazilian primary antiphospholipid syndrome patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) clinical database and repository

    Advances in Rheumatology, Vol. 61, Núm. 1

  3. Clinical presentation of antiphospholipid syndrome

    Lahita’s Systemic Lupus Erythematosus (Elsevier), pp. 561-574

  4. Genetic mechanisms of critical illness in COVID-19

    Nature, Vol. 591, Núm. 7848, pp. 92-98

  5. Mapping the human genetic architecture of COVID-19

    Nature, Vol. 600, Núm. 7889, pp. 472-477

2020

  1. Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study

    Arthritis and Rheumatology, Vol. 72, Núm. 1, pp. 67-77

  2. Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index

    Arthritis and Rheumatology, Vol. 72, Núm. 4, pp. 658-666

2019

  1. The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort

    Seminars in Arthritis and Rheumatism, Vol. 49, Núm. 3, pp. 464-468

2018

  1. Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients

    Arthritis Care and Research, Vol. 70, Núm. 1, pp. 98-103